Exchange: NASDAQ·Updated 03:24 PM EDT
ISRG logo

ISRGIntuitive Surgical Inc

$352.15
$0.95
(0.27%)
Today
Reported EarningsJul 16
Mkt Cap$124.74B
Vol1.7M
News
all
press releases
Is ISRG Winning the Next Phase of Robotic Surgery Beyond Urology?
ISRG is expanding robotic surgery beyond urology as general surgery and newer specialties gain traction, creating fresh avenues for long-term procedure growth.
Zacks
More News
ALGN Stock Up Post Q2 Earnings and Revenue Beat, Margins Rise
Align Technology shares rise after Q2 earnings and revenues beat estimates, fueled by record Clear Aligner shipments and wider non-GAAP margins.
Zacks
LH Stock Down Despite Q2 Earnings and Revenue Beat, Margins Rise
Labcorp's Q2 earnings and revenues surpass estimates, margins expand, and its 2026 outlook is raised, but shares fall 6% in pre-market trading.
Zacks
Boston Scientific Q2 Earnings & Revenues Top Estimates, Stock Climbs
BSX beats Q2 earnings and revenue estimates as cardiovascular growth, strong APAC and LACA sales, and margin expansion lift shares in pre-market.
Zacks
Tuesday's move in Intuitive Surgical is probably more than short covering. How to play it using options
Tuesday's move in Intuitive Surgical is probably more than short covering. How to play it using options...
CNBC: Top News
ISRG Q2 Earnings Call Signals Durable Demand & U.S. Caution
ISRG pairs durable platform demand and higher margin guidance with caution on softer U.S. procedure growth and deferred care.
Zacks
Here's Exactly Why Wall Street Thinks Intuitive Surgical Stock Could Soar 102% Over the Next 12 Months
Key PointsThe da Vinci 5 is driving growth throughout the business...
Nasdaq News: Markets
The ACA Coverage Debate Just Became a $50 Billion Question for Intuitive Surgical
The ACA Coverage Debate Just Became a $50 Billion Question for Intuitive Surgical...
Yahoo! Finance: News
Here's Why You Should Hold Solventum Stock in Your Portfolio for Now
SOLV's innovation, cost savings and strong segment demand support growth, while raw material cost increases remain a key risk.
Zacks
Edwards' Q2 Earnings & Revenues Top Estimates, Stock Rises
EW beats Q2 earnings and revenue estimates as strong TAVR demand, and mitral and tricuspid therapy adoption lift results and guidance.
Zacks
<
1
2
>

Advertisement|Remove ads.